Arrivent Investigative Site — Omaha, Nebraska

Arrivent Investigative Site is a clinical research site located in Omaha, Nebraska, United States 68114.

Crixeo Health Trust Score: 56/100 (POOR). This profile has not yet been claimed by the site owner.

Arrivent Investigative Site has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations.

Sponsors: ArriVent BioPharma, Inc..

Sponsor Feasibility Report

Trust Score: 56/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Arrivent Investigative Site?

Arrivent Investigative Site has a Crixeo Trust Score of 56/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Arrivent Investigative Site conducted?

Arrivent Investigative Site has 1 clinical trials on record, with 1 currently active. Their work covers Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations.

Is Arrivent Investigative Site accredited by Crixeo Health?

Arrivent Investigative Site has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Arrivent Investigative Site?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.